GlassScriptPhysician profile
Shih Te Wen
NPI 1801887997
$10,112.07
in general payments reported to CMS, 2019-2025
30 companies · $1,681 in 2025
The $1,681 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $934 · 2021: $1,279 · 2022: $1,514 · 2023: $1,777 · 2024: $1,883 · 2025: $1,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,341.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,069.14 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,305.49 | 2019-2025 | Farxiga, Wainua, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $1,132.24 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $818.53 | 2019-2024 | Xarelto |
| Amgen INC. | $769.41 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $769.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $551.01 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $320.30 | 2021-2025 | Verquvo, Winrevair, Lagevrio |
| Esperion Therapeutics, INC. | $243.56 | 2020-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $235.39 | 2019-2024 | Opsumit, Uptravi |
| Alnylam Pharmaceuticals INC. | $231.42 | 2022-2025 | Amvuttra, Onpattro |
| Novo Nordisk INC | $226.84 | 2019-2025 | Ozempic |
| Amarin Pharma, INC. | $167.72 | 2020-2022 | |
| Boston Scientific Corporation | $167.50 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor |
| Heartflow, INC. | $157.82 | 2022-2025 | Ffrct |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $132.13 | 2019-2024 | Evkeeza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.90 | 2021-2024 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $109.48 | 2024 | Arcalyst |
| Abbott Laboratories | $93.95 | 2021-2022 | |
| Cmp Pharma, INC. | $69.16 | 2023 | Carospir, Norliqva, Tadliq |
| Medicomp INC | $67.80 | 2024 | Telepatch Cardiac Monitor |
| Kiniksa Pharmaceuticals, LTD. | $67.29 | 2021-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $60.94 | 2023-2024 | Inpefa |
| Baxter Healthcare | $51.72 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Philips North America LLC | $39.77 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $33.73 | 2021 | |
| Recor Medical INC | $27.93 | 2024 | Paradise Renal Denervation System |
| Biotronik INC. | $26.54 | 2024 | |
| Cvrx, INC. | $23.73 | 2023 | Barostim Neo System |
| Medtronic, INC. | $16.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shih Te Wen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.